# Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Source: https://onco.cc/trials/nct01102426/  
OnCo record `nct01102426` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Plitidepsin and Dexamethasone in Multiple myeloma, run by PharmaMar, completed.

## Summary

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma is a phase 3 interventional study registered as NCT01102426 by PharmaMar, with 255 participants recorded, started 2010-06 and reaching its primary completion in 2017-11. Interventions recorded: Plitidepsin, Dexamethasone. Conditions recorded: Relapsed/Refractory Multiple Myeloma.

Linked to the drug Plitidepsin because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-24
- Also known as: ADMYRE
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01102426
- Phase: 3
- Setting: Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
- Sponsor: PharmaMar
- Enrolled: 255
- Outcomes: Progression Free Survival (PFS) as Per Intention-to-treat (ITT): Plitidepsin+Dexamethasone 2.6 months vs Dexamethasone 1.7 months, HR 0.65; Percentage of Participants With Progression Free Survival (PFS) as Per Intention-to-treat (ITT) at 6 Months: Plitidepsin+Dexamethasone 20% vs Dexamethasone 10%; Overall Survival: Plitidepsin+Dexamethasone 11.6 months vs Dexamethasone 8.9 months, HR 0.797; Overall Response Rate (Independent Review Committee): Plitidepsin+Dexamethasone 22.8% vs Dexamethasone 3.6%

## Sources

- ClinicalTrials.gov NCT01102426: https://clinicaltrials.gov/study/NCT01102426

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- drugs: [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Plitidepsin](https://onco.cc/drugs/plitidepsin/)
- companies: [PharmaMar](https://onco.cc/companies/pharmamar/)

---
JSON: https://onco.cc/api/v1/entities/nct01102426.json